<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556191</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-1003</org_study_id>
    <nct_id>NCT01556191</nct_id>
  </id_info>
  <brief_title>Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR</brief_title>
  <acronym>LADIE</acronym>
  <official_title>Phase II Randomised Clinical Trial Evaluating an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Versus an EGFR-TKI Combined With an Anti-oestrogen Treatment (Fulvestrant) in Women With Advanced Stage Non-squamous Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung Cancer is to become the first cause of death related to cancer in France as it's already
      the case in United States. At Present, Lung Cancer in women and in men is treated similarly.
      Nevertheless, numerous studies shows that lung cancer in women has specificities : at the
      time of the diagnosis female patients are younger, there are less clinical signs, clinical
      stages are earlier, histology is often adenocarcinoma. The link with tabagism is weaker .
      Sensitivity to tabagism is higher (more cancer in women with the same tabagism). Response
      rate to chemotherapy is better. Prognosis is better

      Numerous hypotheses have been put forward to account for the specific characteristics of
      female lung cancer described above.

        -  One hypothesis is that there are different genetic anomalies in women. Some studies show
           an increase of EGFR mutation and HER2 expression and a decrease of expression of repair
           enzymes (ERCC1, RRM1, BRCA) which can explain the increase sensitivity to tabagism and
           to chemotherapy.

        -  Another hypothesis is that hormones play a role in oncogenesis. Indeed, lung cancer
           presents hormonal risk factors : pre-menopause, less than 3 kids, short menstrual cycle,
           hormone replacement therapy. Estrogens would have a deleterious effect on cancer
           incidence and on survival of lung cancer in women. Cellular and animal models show that
           ER pathway is activated in lung cancer and participates in oncogenesis.

        -  Moreover an interaction between RE and EGFR pathway has been demonstrated on lung cancer
           cell lines and mouse models.

      EGFR-TKI have shown benefit in women with wild type EGFR or unknown status (with erlotinib)
      and in women with EGFR mutations (with gefitinib). In this study, the use of these two
      treatment will be in accordance with their market authorisations.

      The objective of this study is to test the addition of an anti-estrogen (fulvestrant) to
      EGFR-TKI. Fulvestrant is a pure anti-oestrogen that binds to ER, blocks it and accelerates
      its breakdown. It has a market authorisation in breast cancer. Furthermore the association
      between EGFR-TKI and anti-estrogen could have a synergetic effect due to interaction between
      RE and EGFR pathways .
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>Around nine months</time_frame>
    <description>From date of randomization until the date of first progression for EGFR mutated patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Around three months</time_frame>
    <description>From date of randomization until the date of first progression for EGFR wild type patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity of EGFR-TKI and fulvestrant</measure>
    <time_frame>Around three months</time_frame>
    <description>The number of patients for whom at least an adverse event will have been reported, the number of events, according to the relation to the treatment, the intensity, and the cycle of appearance for EGFR WT patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Around three months</time_frame>
    <description>For EGFR WT patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Around three months</time_frame>
    <description>For EGFR WT patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity of EGFR-TKI and fulvestrant</measure>
    <time_frame>Around Nine months</time_frame>
    <description>The number of patients for whom at least an adverse event will have been reported, the number of events, according to the relation to the treatment, the intensity, and the cycle of appearance for EGFR mutated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Around nine months</time_frame>
    <description>For EGFR-Mutated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Around nine months</time_frame>
    <description>For EGFR mutated patients</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">394</enrollment>
  <condition>Stage IV Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Gefinitib + Fulvestrant (patient with EGFR mutations)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib (wild type patients)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib + Fulvestrant (wild type patients)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefinib (patient with EGFR mutations)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>250 mg per day (oral)</description>
    <arm_group_label>Gefinitib + Fulvestrant (patient with EGFR mutations)</arm_group_label>
    <arm_group_label>Gefinib (patient with EGFR mutations)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose</description>
    <arm_group_label>Gefinitib + Fulvestrant (patient with EGFR mutations)</arm_group_label>
    <arm_group_label>Erlotinib + Fulvestrant (wild type patients)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150 mg per day (oral)</description>
    <arm_group_label>Erlotinib (wild type patients)</arm_group_label>
    <arm_group_label>Erlotinib + Fulvestrant (wild type patients)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed predominant non-squamous, non-small cell lung cancer

          -  The presence of analysable tissue for the research of EGFR activating mutation.
             Analysis must be performed in INCa-labelled laboratories or platforms according to a
             validated technique

          -  Not suitable for radiation, inoperable stage III or stage IV

          -  Patients with an EGFR mutation must never have taken chemotherapy or must be in
             progression after only one previous line of chemotherapy (including maintenance).
             Patients without an EGFR mutation must have received one or two lines of chemotherapy
             beforehand. Maintenance chemotherapy is not considered to be a treatment line.
             Adjuvant chemotherapy is not considered to be a first line of treatment if it dates
             back to over a year

          -  Female

          -  Menopausal: older than 60 years of age or history of ovariectomy or younger than 60
             years old with amenorrhoea for more than 12 months or an FSH rate that corresponds to
             a post-menopausal rate (according to the laboratory)

        Exclusion Criteria:

          -  History of cancer except for skin cancer or cancer dating from over five years ago and
             considered to be cured

          -  Known or suspected Cerebral metastases or spinal cord compression unless they are
             asymptomatic without treatment or stable after being treated by surgery and/or
             radiation therapy. Corticosteroid treatments for symptoms must have discontinued for
             more than four weeks

          -  Pregnancy and breast-feeding

          -  Patient taking hormone replacement therapy for menopause that has not been stopped two
             weeks before the start of the trial treatment

          -  A change in bone marrow, kidney and liver functions inconsistent with treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien MAZIERES, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Annemasse - CH</name>
      <address>
        <city>Ambilly</city>
        <zip>74100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Europe</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angers - CHU</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Besancon - Pneumologie</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bobigny - Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré - Pneumologie</name>
      <address>
        <city>Boulogne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Béziers - CH</name>
      <address>
        <city>Béziers</city>
        <zip>34525</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caen - Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caen - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cahors - CH</name>
      <address>
        <city>Cahors</city>
        <zip>46000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chambéry - CH</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Cholet - Pneumologie</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clamart - Hôpital Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des Cèdres</name>
      <address>
        <city>Cornebarrieu</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Créteil - CHI</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Dax</name>
      <address>
        <city>Dax</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dijon - CAC</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grenoble - CHU</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chartres - CH</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier - Pneumologie</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU (Hôpital Calmette) - Pneumologie</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Longjumeau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord - Oncologie Multidisciplinaire &amp; Innovations Thérapeutiques</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique du Val de Sambre</name>
      <address>
        <city>Maubeuge</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mont de Marsan - CH</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mulhouse - CH</name>
      <address>
        <city>Mulhouse</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes - Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevers - CH</name>
      <address>
        <city>Nevers</city>
        <zip>58033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon - Pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIA Val-de-Grâce</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat - Claude - Bernard</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris - Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pau - CH</name>
      <address>
        <city>Pau</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perpignan - Ch</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL - Lyon Sud (Pneumologie)</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Rambouillet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen - CHU</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Quentin - CH</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strasbourg - NHC</name>
      <address>
        <city>Strasbourg</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suresnes - Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Talent - Clinique mutualiste Bénigne-Joly</name>
      <address>
        <city>Talent</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulouse - CHU Larrey</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tourcoing - CH</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Pneumologie</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versailles - CH</name>
      <address>
        <city>Versailles</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI de la Haute-Saône - Pneumologie</name>
      <address>
        <city>Vesoul</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Villefranche - Pneumologie</name>
      <address>
        <city>Villefranche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ifct.fr</url>
    <description>IFCT official website</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2012</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estrogen Antagonists</mesh_term>
    <mesh_term>Estrogen Receptor Modulators</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

